Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Pabst

Showing results (171-180 of 332) with videos related to

Pageof 34
Sort By:
Cells|September 9, 2022
Experiences with Glofitamab Administration following CAR T Therapy in Patients with Relapsed Mantle Cell LymphomaAlexander D Heini, Ulrike Bacher, Naomi Porret, et al.
Leukemia & Lymphoma|June 19, 2012
Autotransplant for Hodgkin lymphoma after failure of upfront BEACOPP escalated (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone)Luciano Wannesson, Mario Bargetzi, Anne Cairoli, et al.
Hematological Oncology|July 15, 2023
Effect of MAPK activation via mutations in NRAS, KRAS and BRAF on clinical outcome in newly diagnosed multiple myelomaCamille Perroud, Dario Thurian, Martin Andres, et al.
BMC Medical Genomics|September 22, 2022
Correlation of plasma cell assessment by phenotypic methods and molecular profiles by NGS in patients with plasma cell dyscrasiasEkaterina Rebmann Chigrinova, Naomi A Porret, Martin Andres, et al.
Leukemia & Lymphoma|January 9, 2019
Prolonged survival with increasing duration of lenalidomide maintenance after autologous transplant for multiple myelomaIsabel G Amsler, Barbara Jeker, Behrouz Mansouri Taleghani, et al.
Bone Marrow Transplantation|June 10, 2018
Peripheral flow-MRD status at the time of autologous stem cell collection predicts outcome in multiple myelomaIvana Moor, Vera U Bacher, Barbara Jeker, et al.
American Journal of Hematology|April 13, 2018
Optimizing the pretransplant regimen for autologous stem cell transplantation in acute myelogenous leukemia: Better outcomes with busulfan and melphalan compared with busulfan and cyclophosphamide in high risk patients autografted in first complete remission: A study from the acute leukemia working party of the EBMTNorbert Claude Gorin, Myriam Labopin, Didier Blaise, et al.
Cancer Research|September 9, 2011
Aberrant lipid metabolism in hepatocellular carcinoma revealed by plasma metabolomics and lipid profilingAndrew D Patterson, Olivier Maurhofer, Diren Beyoglu, et al.
Cancers|May 25, 2024
Daratumumab during Myeloma Induction Therapy Is Associated with Impaired Stem Cell Mobilization and Prolonged Post-Transplant Hematologic RecoveryJulian Mehl, Dilara Akhoundova, Ulrike Bacher, et al.
British Journal of Haematology|April 29, 2006
Mutations of the myeloid transcription factor CEBPA are not associated with the blast crisis of chronic myeloid leukaemiaThomas Pabst, Erica Stillner, Donna Neuberg, et al.
Pageof 34

Showing results (171-180 of 332) with videos related to

Sort By:
Pageof 34
Cells|September 9, 2022
Experiences with Glofitamab Administration following CAR T Therapy in Patients with Relapsed Mantle Cell LymphomaAlexander D Heini, Ulrike Bacher, Naomi Porret, et al.
Leukemia & Lymphoma|June 19, 2012
Autotransplant for Hodgkin lymphoma after failure of upfront BEACOPP escalated (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone)Luciano Wannesson, Mario Bargetzi, Anne Cairoli, et al.
Hematological Oncology|July 15, 2023
Effect of MAPK activation via mutations in NRAS, KRAS and BRAF on clinical outcome in newly diagnosed multiple myelomaCamille Perroud, Dario Thurian, Martin Andres, et al.
BMC Medical Genomics|September 22, 2022
Correlation of plasma cell assessment by phenotypic methods and molecular profiles by NGS in patients with plasma cell dyscrasiasEkaterina Rebmann Chigrinova, Naomi A Porret, Martin Andres, et al.
Leukemia & Lymphoma|January 9, 2019
Prolonged survival with increasing duration of lenalidomide maintenance after autologous transplant for multiple myelomaIsabel G Amsler, Barbara Jeker, Behrouz Mansouri Taleghani, et al.
Bone Marrow Transplantation|June 10, 2018
Peripheral flow-MRD status at the time of autologous stem cell collection predicts outcome in multiple myelomaIvana Moor, Vera U Bacher, Barbara Jeker, et al.
American Journal of Hematology|April 13, 2018
Optimizing the pretransplant regimen for autologous stem cell transplantation in acute myelogenous leukemia: Better outcomes with busulfan and melphalan compared with busulfan and cyclophosphamide in high risk patients autografted in first complete remission: A study from the acute leukemia working party of the EBMTNorbert Claude Gorin, Myriam Labopin, Didier Blaise, et al.
Cancer Research|September 9, 2011
Aberrant lipid metabolism in hepatocellular carcinoma revealed by plasma metabolomics and lipid profilingAndrew D Patterson, Olivier Maurhofer, Diren Beyoglu, et al.
Cancers|May 25, 2024
Daratumumab during Myeloma Induction Therapy Is Associated with Impaired Stem Cell Mobilization and Prolonged Post-Transplant Hematologic RecoveryJulian Mehl, Dilara Akhoundova, Ulrike Bacher, et al.
British Journal of Haematology|April 29, 2006
Mutations of the myeloid transcription factor CEBPA are not associated with the blast crisis of chronic myeloid leukaemiaThomas Pabst, Erica Stillner, Donna Neuberg, et al.
Pageof 34